<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>113 S1425 IS: Dietary Supplement Labeling Act of 2013</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2013-08-01</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 1425</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130801">August 1, 2013</action-date>
			<action-desc><sponsor name-id="S253">Mr. Durbin</sponsor> (for himself
			 and <cosponsor name-id="S341">Mr. Blumenthal</cosponsor>) introduced the
			 following bill; which was read twice and referred to the
			 <committee-name committee-id="SSHR00">Committee on Health, Education, Labor,
			 and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To improve the safety of dietary supplements by amending
		  the Federal Food, Drug, and Cosmetic Act to require manufacturers of dietary
		  supplements to register dietary supplements with the Food and Drug
		  Administration and to amend labeling requirements with respect to dietary
		  supplements.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short
			 title</header><text display-inline="no-display-inline">This Act may be cited as
			 the <quote><short-title>Dietary Supplement Labeling Act of
			 2013</short-title></quote>.</text>
		</section><section id="idD53F5E1E10AC44A1BD1B41F93B4C4585"><enum>2.</enum><header>Regulation of
			 dietary supplements</header>
			<subsection id="id0D345A6C8574472C8EC67399ED787520"><enum>(a)</enum><header>Registration
			 requirements</header>
				<paragraph id="id245B1C1A53654C90A1A0BF5E518DF813"><enum>(1)</enum><header>In
			 general</header><text>Section 415(a) of the Federal Food, Drug, and Cosmetic
			 Act (<external-xref legal-doc="usc" parsable-cite="usc/21/350d">21 U.S.C. 350d(a)</external-xref>) is amended by adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="idC9413F5E052745B3AB36BD4FF70052EE" style="OLC">
						<paragraph id="id64E07DB1812D4835B2A645648F380202"><enum>(6)</enum><header>Requirements
				with respect to dietary supplements</header>
							<subparagraph id="id69AF7E581F2E416EAB3E0AEF2D108EE1"><enum>(A)</enum><header>In
				general</header><text>A facility engaged in manufacturing or processing dietary
				supplements that is required to register under this section shall comply with
				the requirements of this paragraph, in addition to the other requirements of
				this section.</text>
							</subparagraph><subparagraph id="idD6AC7735A2FE4DC29E0682CEBB04408A"><enum>(B)</enum><header>Additional
				information</header>
								<clause id="id4F355F37CB23493EA7B9775FDAE971A4"><enum>(i)</enum><header>In
				general</header><text>A facility described in subparagraph (A) shall submit a
				registration under paragraph (1) that includes, in addition to the information
				required under paragraph (2)—</text>
									<subclause id="idC4E298F1B69C4C8BA5B515B4373E859C"><enum>(I)</enum><text>a description of
				each dietary supplement manufactured or processed by such facility;</text>
									</subclause><subclause id="id00615FB81CD745A8B089784F23C03B39"><enum>(II)</enum><text>a list of all
				ingredients in each such dietary supplement; and</text>
									</subclause><subclause id="id8ECC958A35414EDD886A175CA6FF5E12"><enum>(III)</enum><text>a copy of the
				label for each such dietary supplement.</text>
									</subclause></clause><clause id="id06E4824B51854424B884DE0A8DBD1390"><enum>(ii)</enum><header>Public
				availability</header><text>The Secretary shall make the information provided
				under clause (i) publicly available, including by posting such information on
				the Internet Web site of the Food and Drug Administration.</text>
								</clause></subparagraph><subparagraph id="idC610575330C7475E93E9487EBD8F8429"><enum>(C)</enum><header>Registration
				with respect to new, reformulated, and discontinued dietary
				supplements</header>
								<clause id="id00E0ACCAD98B445181A2482763E1E431"><enum>(i)</enum><header>In
				general</header><text>Not later than the date described in clause (ii), if a
				facility described in subparagraph (A)—</text>
									<subclause id="idD2229A2CA422472FA0CE36B065556F7B"><enum>(I)</enum><text>manufactures or
				processes a dietary supplement that the facility previously did not manufacture
				or process and for which the facility did not submit the information required
				under subclauses (I) through (III) of subparagraph (B)(i);</text>
									</subclause><subclause id="id1E6990A0AE4147958F120FE53DA84B03"><enum>(II)</enum><text>reformulates a
				dietary supplement for which the facility previously submitted the information
				required under subclauses (I) through (III) of subparagraph (B)(i); or</text>
									</subclause><subclause id="id97928F73345444B59295DDDAC45A9ACF"><enum>(III)</enum><text>no longer
				manufactures or processes a dietary supplement for which the facility
				previously submitted the information required under subclauses (I) through
				(III) of subparagraph (B)(i),</text>
									</subclause><continuation-text continuation-text-level="clause">such facility
				shall submit to the Secretary an updated registration describing the change
				described in subclause (I), (II), or (III) and, in the case of a facility
				described in subclause (I) or (II), containing the information required under
				subclauses (I) through (III) of subparagraph (B)(i).</continuation-text></clause><clause id="id4919F2037175472CBE92BE0A1B85656C"><enum>(ii)</enum><header>Date
				described</header><text>The date described in this clause is—</text>
									<subclause id="id43F58F3770564474BEEEF43715304914"><enum>(I)</enum><text>in the case of a
				facility described in subclause (I) of clause (i), 30 days after the date on
				which such facility first markets the dietary supplement described in such
				subclause;</text>
									</subclause><subclause id="id5DFF62379B9B485C86F75A2805FBC5D8"><enum>(II)</enum><text>in the case of a
				facility described in subclause (II) of clause (i), 30 days after the date on
				which such facility first markets the reformulated dietary supplement described
				in such subclause; or</text>
									</subclause><subclause id="id38DBDF3C8BFC408090AF0EC0B933EEF8"><enum>(III)</enum><text>in the case of
				a facility described in subclause (III) of clause (i), 30 days after the date
				on which such facility removes the dietary supplement described in such
				subclause from the
				market.</text>
									</subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph><paragraph id="id6B20D982E08E46AC9A9C3295FBE7368B"><enum>(2)</enum><header>Enforcement</header><text>Section
			 403 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/343">21 U.S.C. 343</external-xref>) is amended by
			 adding at the end the following:</text>
					<quoted-block display-inline="no-display-inline" id="id792CFA59648D460495A0652B95289680" style="OLC">
						<subsection id="id186129E3CE7147718A5CC9ADB83946F2"><enum>(z)</enum><text>If it is a
				dietary supplement for which a facility is required to submit the registration
				information required under section 415(a)(6) and such facility has not complied
				with the requirements of such section 415(a)(6) with respect to such dietary
				supplement.</text>
						</subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection><subsection id="id8AD67BBC62434B71AFC3D997F9D1E3C5"><enum>(b)</enum><header>Labeling</header>
				<paragraph id="id425DDE36BB4942479A795DA5CB38E658"><enum>(1)</enum><header>Establishment
			 of labeling requirements</header><text>Chapter IV of the Federal Food, Drug,
			 and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/341">21 U.S.C. 341 et seq.</external-xref>) is amended by inserting after section
			 411 the following:</text>
					<quoted-block display-inline="no-display-inline" id="id00BB4FA3A76F4830AB21D4316BF6F1E1" style="OLC">
						<section id="id15D2CB8D320A4CFCB6880626F4A5D933"><enum>411A.</enum><header>Dietary
				supplements</header>
							<subsection id="idA9BC4B086D534E46B3A0D51A730177D6"><enum>(a)</enum><header>Dietary
				supplement ingredients</header><text>Not later than 1 year after the date of
				enactment of the <short-title>Dietary Supplement Labeling
				Act of 2013</short-title>, the Secretary shall compile a list of dietary
				supplement ingredients and proprietary blends of ingredients that the Secretary
				determines could cause potentially serious adverse events, drug interactions,
				or contraindications, or potential risks to subgroups such as children and
				pregnant or breastfeeding women.</text>
							</subsection><subsection id="id7460DDE0D536492785E0E41C147EFAF0"><enum>(b)</enum><header>IOM
				study</header><text>The Secretary shall seek to enter into a contract with the
				Institute of Medicine under which the Institute of Medicine shall evaluate
				dietary supplement ingredients and proprietary blends of ingredients, including
				those on the list compiled by the Secretary under subsection (a), and
				scientific literature on dietary supplement ingredients and, not later than 18
				months after the date of enactment of the <short-title>Dietary Supplement Labeling Act of 2013</short-title>,
				submit to the Secretary a report evaluating the safety of dietary supplement
				ingredients and proprietary blends of ingredients the Institute of Medicine
				determines could cause potentially serious adverse events, drug interactions,
				or contraindications, or potential risks to subgroups such as children and
				pregnant or breastfeeding women.</text>
							</subsection><subsection id="id94579B3C478C425C9FBA7E06E9115040"><enum>(c)</enum><header>Establishment
				of requirements</header><text>Not later than 2 years after the date on which
				the Institute of Medicine issues the report under subsection (b), the
				Secretary, after providing for public notice and comment and taking into
				consideration such report, shall—</text>
								<paragraph id="idA4123E08CD1F4CBCB0B8FE96664984C1"><enum>(1)</enum><text>establish
				mandatory warning label requirements for dietary supplement ingredients that
				the Secretary determines to cause potentially serious adverse events, drug
				interactions, or contraindications, or potential risks to subgroups; and</text>
								</paragraph><paragraph id="idEA6AA22100604C549D5505E462D87426"><enum>(2)</enum><text>identify
				proprietary blends of ingredients for which, because of potentially serious
				adverse events, drug interactions, or contraindications, or potential risks to
				subgroups such as children and pregnant or breastfeeding women, the weight per
				serving of the ingredient in the proprietary blend shall be provided on the
				label.</text>
								</paragraph></subsection><subsection id="idFDECE45C72DE4D9EABC5AC77186BF0B2"><enum>(d)</enum><header>Updates</header><text>As
				appropriate, the Secretary, after providing for public notice and comment,
				shall update—</text>
								<paragraph id="idB911FF7FA29F4FA39AA080A525434663"><enum>(1)</enum><text>the list compiled
				under subsection (a);</text>
								</paragraph><paragraph id="idBB98DA125B914D29AE6BD9B3E7038C87"><enum>(2)</enum><text>the mandatory
				warning label requirements established under paragraph (1) of subsection (c);
				and</text>
								</paragraph><paragraph id="id1B4413A2044347D7B472592DCE639197"><enum>(3)</enum><text>the requirements
				under paragraph (2) of subsection
				(c).</text>
								</paragraph></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph><paragraph id="id34AB51AF1EAE4ECBA4DABB5197708B30"><enum>(2)</enum><header>Enforcement</header><text>Section
			 403 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/343">21 U.S.C. 343</external-xref>) is
			 amended—</text>
					<subparagraph id="id7DECAE1FCBA9463DA4E1C7A2F59FA832"><enum>(A)</enum><text>in paragraph
			 (q)(5)(F)(ii), by inserting <quote>, and for each proprietary blend identified
			 by the Secretary under section 411A(c)(2), the weight of such proprietary
			 blend,</quote> after <quote>ingredients)</quote>; and</text>
					</subparagraph><subparagraph id="id7D9A4A40423047C295E59C4563ECA25E"><enum>(B)</enum><text>in paragraph
			 (s)(2)—</text>
						<clause id="id3620A93AE2744EDD9CDB56D13432B1D2"><enum>(i)</enum><text>in
			 clause (A)(ii)(II), by inserting <quote>, and for each proprietary blend
			 identified by the Secretary under section 411A(c)(2), the weight of each such
			 proprietary blend per serving</quote> before the semicolon at the end;</text>
						</clause><clause id="id2AB53E426DEB42F68F163D9C9DB7B68A"><enum>(ii)</enum><text>in
			 clause (D)(iii), by striking <quote>or</quote> at the end;</text>
						</clause><clause id="id05F3E2B57BC04D97BAAAF5976C9377EC"><enum>(iii)</enum><text>in clause
			 (E)(ii)(II), by striking the period at the end and inserting a semicolon;
			 and</text>
						</clause><clause id="idF67EF42B78B640A8833F17504CC3AA32"><enum>(iv)</enum><text>by
			 adding at the end the following:</text>
							<quoted-block display-inline="no-display-inline" id="id55CA67EB1AC44CA3ACA335909DAA98AF" style="OLC">
								<subparagraph id="id37D31E866D9D482C866D3EDF10180D14"><enum>(F)</enum><text>the label does
				not include information with respect to potentially serious adverse events,
				drug interactions, or contraindications, or potential risks to subgroups such
				as children and pregnant or breastfeeding women, as required under section
				411A(c)(1); or</text>
								</subparagraph><subparagraph id="id213E4D5322624958939F42007A69BBE8"><enum>(G)</enum><text>the label does
				not include the batch
				number.</text>
								</subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
						</clause></subparagraph></paragraph></subsection><subsection id="id4AA2AB794A5F485DBA6C6E6CB105ED28"><enum>(c)</enum><header>Structure and
			 function claims</header><text>Section 403(r)(6)(B) of the Federal Food, Drug,
			 and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/343">21 U.S.C. 343(r)(6)(B)</external-xref>) is amended by inserting <quote>, and
			 provides such substantiation to the Secretary, as the Secretary may
			 require</quote> after <quote>misleading</quote>.</text>
			</subsection><subsection id="id9C530134F20245DD98CC9480C60C2BBA"><enum>(d)</enum><header>Conventional
			 foods</header><text>The Secretary of Health and Human Services, not later than
			 1 year after the date of enactment of this Act and after providing for public
			 notice and comment, shall establish a definition for the term
			 <term>conventional food</term> for purposes of the Federal Food, Drug, and
			 Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/301">21 U.S.C. 301 et seq.</external-xref>). Such definition shall take into account
			 conventional foods marketed as dietary supplements, including products marketed
			 as dietary supplements that simulate conventional foods.</text>
			</subsection></section></legis-body>
</bill>


